Navigation Links
China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
Date:11/23/2007

one-time loss from discontinue operations of $2 million during the same nine month period in 2006. Therefore, the net loss for the nine month period ending September 30, 2007 was $11.7 million versus a net loss of $1.9 million for the same period one year ago.

Balance Sheet and Debt Conversion

As of September 30, 2007, total assets were $34.4 million and total liabilities plus minority interest were $36.1 million. Subsequent to the quarter, the Company entered into an agreement on November 19, 2007, under which the principal amount of the $11.5 million Loan owed to RimAsia in connection with the Enshi acquisitions plus unpaid interest of $1,008,534, which totals $12,508,534 will be conditionally converted in full into 6,185,607 shares of senior redeemable convertible preferred shares of the Company. Thus the above listed liabilities would be decreased $12.5 million while the book value of the Company would increase by the same amount. Therefore current shareholder equity of negative $1.7 million, would improve to $10.8 million or $.30 per share based on the 36.5 million shares currently outstanding, and $.22 per fully diluted share with the preferred included.

These new preferred shares have an effective conversion price of $1.011. Additionally, the exercise price of $1.375 for the 12 million existing warrants exercisable into the Company's common stock previously issued to and currently held by RimAsia in connection with the extension of the Loan financing will be lowered to $1.26 per share and the term of the Existing Warrants extended to 4.5 years from the closing date. This is conditioned on the Company signing a letter of intent for acquisition of a new company or for the injection of the remaining 49% equity stake of Erye not already owned by the Company before January 15, 2008, having such acquisition closed before June 30, 2008.

Subsequent Events -- New Drug Development Agreement

Subsequent to the end of our third quarter o
'/>"/>

SOURCE China Biopharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Brook, NY (PRWEB) August 01, 2014 ... @APDN), a provider of DNA-based anti-counterfeiting technology and product ... August 12, 2014 to discuss its fiscal third quarter ... filed with the SEC by the end of the ... DNA Sciences, Inc. management will host a conference call ...
(Date:8/1/2014)... AACC, a global scientific and medical professional ... an updated brand identity today that reflects the organization,s ... healthcare environment and continue to do what they do ... the care they need. " The ... essential role in saving lives and making people healthier," ...
(Date:8/1/2014)... Toronto, Canada (PRWEB) August 01, 2014 ... what should it cost? This webinar will discuss how ... construction. , Join speakers Bob Allen, Senior Director ... Director of Process Engineering at Fluor Industrial Services, and ... supporting Manufacturing Asset Planning at Amgen, as they provide ...
(Date:7/31/2014)... 2014 Food and natural product ... for food alternatives that offer variety, as well ... ingredient market has numerous players operating in the ... Force Technology (VFT). VFT is a science-driven ... patterns, all tested to produce stable, effective and ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3AACC Debuts Refreshed Brand Identity 2Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2
... importance on ... indication-specific FDA approval, WALTHAM, Mass., April 2, 2008 ... into the marketing of biliary,stents for off-label uses in the ... could become a key focus for,stent manufacturers. A recent study ...
... 25 Global Pharmaceutical Companies Select Drug ... MOUNTAIN VIEW, Calif., April 2, 2008 ,Pharsight ... of software,strategic consulting, and regulatory services for optimizing ... global pharmaceutical,companies have become customers for its Drug ...
... Nutritional Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... a wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin ... purchase order for the international,distribution of the Resurgex(R) line in ...
Cached Biology Technology:Off-Label Stent Use: How Important Are FDA Approvals to Physicians? 2Pharsight Signs Two New DMX(R) License Customers 2Pharsight Signs Two New DMX(R) License Customers 3Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3
(Date:7/31/2014)... Researchers who studied 100 twin pairs have identified a ... on less than six hours of sleep per night. ... the effects of sleep deprivation. , Results show that a ... had an average nightly sleep duration of only five ... non-carrier twin, who slept for about six hours and five ...
(Date:7/31/2014)... in German . ... similar to a sponge that soaks up liquids. Hence, ... or greenhouse gases. However, loading of many MOFs is ... (KIT) now report in Nature Communications that ... surface. This can be prevented by water-free synthesis and ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
Breaking Biology News(10 mins):Study of twins discovers gene mutation linked to short sleep duration 2Free pores for molecule transport 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... Scientists at the University of Idaho currently are involved ... been running rampant for the past decade. But the killer,s ... Instead, it,s on the minds of ecologists on every continent ... (Bd). It is a "chytrid" fungus that lives on ...
... to slam the Gulf Coast, and even reason to believe ... How we handle them will be the primary topic of ... Global Climate Impact in the Gulf Coast Conference Oct. 29-31. ... and Evacuation from Disaster Center, primary sponsor of the conference. ...
... 2008Three years after Hurricane Katrina devastated New Orleans, people ... city,s floodwall system. A new article in the fall ... 3) suggests that Formosan subterranean termites played a large ... Louisiana State University AgCenter, discovered Formosan subterranean termites (Coptotermes ...
Cached Biology News:Modern genetics vs. ancient frog-killing fungus 2Modern genetics vs. ancient frog-killing fungus 3Weather woes emphasize need for SSPEED 2Did termites help Katrina destroy New Orleans floodwalls? 2
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by the lipoxygenation of linoleic acid ... detected in atherosclerotic plaques, as an esterified component ...
Biology Products: